AIHealthcare

Unlearn.AI, Inc. is a privately held healthcare AI company founded in 2017 that develops AI-generated digital twins of clinical-trial participants. Its Unlearn Platform and Digital Twin Generators forecast individual patient outcomes under control or standard-of-care treatment, supporting TwinRCTs, synthetic or external comparator arms, trial design, and clinical-development decisions. The company primarily serves pharmaceutical companies, biotechnology firms, and academic research organizations, with stated activity across neuroscience, immunology, metabolic disease, and other therapeutic areas. Unlearn reports regulatory engagement in the United States and Europe; its PROCOVA methodology has been qualified by the European Medicines Agency for certain Phase 2 and 3 trials involving continuous outcomes. Its market position is that of a specialized clinical-trial AI and digital-twin provider rather than a general-purpose healthcare AI company, with partnerships or collaborations involving major pharmaceutical and biotechnology organizations. No reliable public information was found establishing a public listing, current valuation, revenue, or a definitive market-share ranking.